Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAI, IBRX-042, and Nab-paclitaxel in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
NCT07628062Phase 2Not yet recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Jul 2026
- Primary completion
- Dec 2030
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, hAd5-HPV vaccine in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by ImmunityBio, Inc.. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nogapendekin alfa inbakicepthAd5-HPV vaccine
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07628062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07628062.